Last reviewed · How we verify
Everolimus Tab.
Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.
Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation. Used for Advanced renal cell carcinoma, Breast cancer (hormone receptor-positive, HER2-negative), Neuroendocrine tumors of pancreatic origin.
At a glance
| Generic name | Everolimus Tab. |
|---|---|
| Also known as | CertiroBell Tab. |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | mTOR inhibitor |
| Target | mTOR (mammalian target of rapamycin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Everolimus is an mTOR inhibitor that suppresses cell cycle progression and angiogenesis by blocking mTOR signaling. It is used primarily in oncology to slow or stop the growth of cancer cells, and also has immunosuppressive properties useful in organ transplantation and certain autoimmune conditions.
Approved indications
- Advanced renal cell carcinoma
- Breast cancer (hormone receptor-positive, HER2-negative)
- Neuroendocrine tumors of pancreatic origin
- Subependymal giant cell astrocytoma (SEGA)
- Renal angiomyolipoma associated with tuberous sclerosis complex
Common side effects
- Stomatitis/mouth ulcers
- Infections
- Rash
- Diarrhea
- Fatigue
- Anemia
- Hyperglycemia
- Hyperlipidemia
Key clinical trials
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (PHASE2, PHASE3)
- Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) (PHASE2)
- Everolimus Trial in Laryngotracheal Stenosis (EARLY_PHASE1)
- Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) (PHASE1, PHASE2)
- Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC) (PHASE2)
- A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment (PHASE2)
- Rapalog Pharmacology (RAP PAC) Study (PHASE1)
- Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |